Medication info
Dapagliflozin Propanediol Hydrate 10 mg

Dapagliflozin Propanediol Hydrate 10 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tablet
Manufacturer / importer
Samchundang Pharmaceutical Co., Ltd.
Appearance
Yellow, bilaterally convex, diamond-shaped film-coated tablet
Packaging
30 tablets/bottle, 30 tablets (10 tablets/AluAlu) x 3
Approval status
Active

MFDS item code 202300026 · Approved 2023.01.03 · Insurance code 651205890

Summary

Main use
Treatment of type 2 diabetes; prevention of worsening of chronic heart failure; slowing the progression of chronic kidney disease
Who takes it
Adults · Children
Adult dose
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10 mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, including insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no prior history of antidiabetic drug treatment, the recommended initial dose of this medicine when administered in combination with metformin is 5 mg once daily or 10 mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - eGFR less than 25 mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
Child dose
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Ingredients

Manufacturer
Samchundang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes; prevention of worsening of chronic heart failure; slowing the progression of chronic kidney disease

  • Type 2 diabetes
  • blood sugar control disorders
  • cardiovascular diseases
  • cardiovascular risk factors
  • chronic heart failure
  • heart failure
  • chronic kidney disease
  • estimated glomerular filtration rate reduction
  • end-stage kidney disease.
View approved original text

This medication is primarily used in conjunction with diet and exercise to improve blood sugar control in patients with type 2 diabetes. It is also beneficial for patients with type 2 diabetes who have cardiovascular disease risk. In patients with chronic heart failure, it reduces the risk of hospitalization due to heart failure and the occurrence of acute situations, and is administered together with other heart failure medications. For patients with chronic kidney disease, it is used to reduce the risks associated with declining kidney function and to lower the risk of cardiovascular and kidney-related mortality. Thus, it is effectively used for patients with complex cardiovascular and kidney diseases. Therefore, this drug is used for blood sugar control, improvement of heart failure symptoms, and inhibition of the progression of chronic kidney disease.

How to take

Adult dose

Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10 mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, including insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no prior history of antidiabetic drug treatment, the recommended initial dose of this medicine when administered in combination with metformin is 5 mg once daily or 10 mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - eGFR less than 25 mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.

Child dose

The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Precautions

This medication should not be used in patients with allergies to the active ingredient or additives, those with type 1 diabetes or diabetic ketoacidosis, and those undergoing dialysis. It should be used cautiously in patients with reduced fluid volume or impaired kidney function, as there is a risk of hypotension or acute kidney injury, thus blood pressure and kidney function should be carefully monitored before and during administration. The blood sugar control effect of this medication varies according to kidney function and is not recommended for patients with significantly impaired kidney function. The most common side effect observed in clinical trials is genital infections, which may occur more frequently in women or patients with a history of infections. Symptoms of hypoglycemia may occur more frequently when this medication is used with insulin or sulfonylureas, so caution is warranted. Dehydration and hypotension symptoms have also been reported, so fluid status should be carefully monitored and medication may need to be temporarily halted if necessary. This drug can cause severe metabolic disturbances known as diabetic ketoacidosis, so if related symptoms arise, inform healthcare providers immediately. There is also an increased risk of urinary tract infections and pyelonephritis, so prompt treatment is needed if infection symptoms occur. Elderly patients or those with impaired kidney function should be used with particular caution due to the higher risk of reduced fluid volume and hypotension. Pregnant or breastfeeding women are advised not to use this medication, and it should be discontinued upon confirmation of pregnancy. Adjustment of insulin or sulfonylurea doses may be required when using this drug, so consultation with the treating physician is necessary. This drug increases urination which can lower blood pressure, so patients with a history of hypotension or those taking diuretics should be monitored closely. During the use of this medication, testing for 1,5-anhydroglucitol for blood sugar control is not recommended, and other methods should be used to manage blood sugar. In case of overdose, there is no specific antidote, so appropriate treatment based on symptoms should be sought, and it has not been confirmed whether this medication can be removed through dialysis. This medication does not significantly affect driving or machine operating abilities, but caution is needed in the event of a risk of hypoglycemia. Store the product out of reach of children and maintain its quality by keeping it in the original container.

Side effects

Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, decreased fluid volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, low back pain, dysuria, polyuria, nocturia, interstitial nephritis, vulvar itching, genital itching, elevated hematocrit, decreased renal creatinine clearance at the beginning of treatment, dyslipidemia, elevated blood creatinine at the beginning of treatment, increased blood urea, weight loss, acute pyelonephritis, rash, angioedema, asthenia, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina pectoris, myocardial infarction, choledocholithiasis, cholangitis, alcoholic liver cirrhosis, depression, suicide attempt, gastric adenocarcinoma, anaphylactic reaction, chest pain, paresthesia, cerebral infarction, nerve compression, uroseptic shock, acute kidney injury, angioedema, vascular headache, orthostatic hypotension, palpitations, anxiety disorders, nocturia, vertigo, tinnitus, insomnia, fatty liver, gallbladder polyp, hair loss, dermatitis, dry skin, allergic dermatitis, contact dermatitis, diabetic foot ulcer, hyperhidrotic eczema, nummular eczema, eczema, hyperkeratosis, nail pigmentation, skin lesions, urticaria, cold sweat, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, ligament sprain, diabetic retinopathy, cough, dyspnea, vaginal discharge, menstrual irregularities, pruritus, herpes simplex, edema, fever, foreign body sensation, facial swelling, facial pain, warmth, influenza-like symptoms, breast mass, erectile dysfunction, benign prostatic hyperplasia, mastalgia, genital rash, menorrhagia, genital edema, uterine bleeding, vaginal bleeding, discomfort of the vulva, urgency, diabetic nephropathy, overactive bladder, microalbuminuria, stress urinary incontinence, hesitancy in urination, urinary stones, abnormal urine, increased blood lactate, lymphocytopenia, vitamin D deficiency, decreased appetite, next syndrome, increased appetite, headache, headache, nasopharyngitis, upper respiratory infection, asthenia, hunger, vaginal discharge, pruritus

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to protect it from air and moisture. Additionally, avoid storing the medication in excessively hot or cold places; it is recommended to store it at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Yellow, bilaterally convex, diamond-shaped film-coated tablet

Package unit

30 tablets/bottle, 30 tablets (10 tablets/AluAlu) x 3

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.